(Q33886818)

29 July 2017

Serum HER2 level measured by dot blot: a valid and inexpensive assay for monitoring breast cancer progression (English)

1 reference

29 July 2017

Li-Duan Tan

1

1 reference

29 July 2017

Yuan-Yuan Xu

2

1 reference

29 July 2017

Yue Yu

3

1 reference

29 July 2017

Xiao-Qing Li

4

1 reference

29 July 2017

Ying Chen

5

1 reference

29 July 2017

Yu-Mei Feng

6

1 reference

29 July 2017

language of work or name

English

0 references

publication date

13 April 2011

1 reference

29 July 2017

1 reference

29 July 2017

6

1 reference

29 July 2017

4

1 reference

29 July 2017

e18764

1 reference

Current technologies for HER2 testing in breast cancer.

29 July 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3076436

Shed HER2 extracellular domain in HER2-mediated tumor growth and in trastuzumab susceptibility

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3076436

Personalizing HER2-targeted therapy in metastatic breast cancer beyond HER2 status: what we have learned from clinical specimens

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3076436

Serum HER2 as a response indicator to various chemotherapeutic agents in tissue HER2 positive metastatic breast cancer

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3076436

5 July 2018

Cancer statistics, 2009

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3076436

Lapatinib: a novel EGFR/HER2 tyrosine kinase inhibitor for cancer.

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3076436

Monitoring the circulating levels of the HER2/neu oncoprotein in breast cancer

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3076436

HER2 testing and correlation with efficacy of trastuzumab therapy.

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3076436

The HER2 extracellular domain as a prognostic and predictive factor in breast cancer

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3076436

Absence of HER2/neu gene expression in osteosarcoma and skeletal Ewing's sarcoma

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3076436

The ErbB signaling network: receptor heterodimerization in development and cancer

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3076436

Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3076436

Soluble c-erbB-2 fragment in serum correlates with disease stage and predicts for shortened survival in patients with early-stage and advanced breast cancer

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3076436

Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3076436

5 July 2018

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0018764

Trastuzumab and vinorelbine as first-line therapy for HER2-overexpressing metastatic breast cancer: multicenter phase II trial with clinical outcomes, analysis of serum tumor markers as predictive factors, and cardiac surveillance algorithm

21 January 2018

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0018764

Evaluation of serum HER2 extracellular domain in early breast cancer patients: correlation with clinicopathological parameters and survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0018764

Prognostic and predictive value of HER2 extracellular domain in metastatic breast cancer treated with lapatinib and paclitaxel in a randomized phase III study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0018764

Serum HER2 extracellular domain in metastatic breast cancer patients treated with weekly trastuzumab and paclitaxel: association with HER2 status by immunohistochemistry and fluorescence in situ hybridization and with response rate

21 January 2018

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0018764

Changes over time of extracellular domain of HER2 (ECD/HER2) serum levels have prognostic value in metastatic breast cancer

21 January 2018

1 reference

12 December 2020

Clinical utility of serial serum c-erbB-2 determinations in the follow-up of breast cancer patients

1 reference

12 December 2020

C-erbB-2 protein in the sera of breast cancer patients

1 reference

12 December 2020

Monitoring serum HER2 levels during neoadjuvant trastuzumab treatment within the GeparQuattro trial

1 reference

12 December 2020

ElevatederbB-2 oncoprotein levels in preoperative and follow-up serum samples define an aggressive disease course in patients with breast cancer

1 reference

12 December 2020

Clinical utility of serum HER-2/neu testing on the Bayer Immuno 1 automated system in breast cancer

1 reference

12 December 2020

Perioperative serum VEGF and extracellular domains of EGFR and HER2 in early breast cancer

1 reference

12 December 2020

C-erbB-2 oncoprotein in the sera and tissue of patients with breast cancer. Utility in prognosis

1 reference

12 December 2020

Prognostic significance of serum c-erbB-2 protein in breast cancer patients

1 reference

12 December 2020

10.1371/JOURNAL.PONE.0018764

Identifiers

DOI

1 reference

29 July 2017

0 references

1 reference

29 July 2017

1 reference